Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2014
09/25/2014WO2014146775A1 Pharmaceutical composition comprising a fluoroquinolone antibacterial agent and method for the preparation thereof
09/25/2014WO2014146747A1 Piperazine derivatives as fasn inhibitors
09/25/2014WO2014146699A1 Antagonists of the cannabionoid receptor cb1 for use in the treatment of diseases associated with neuronal dendritic abnormalities
09/25/2014WO2014146606A1 C-triaryl glucoside sglt-2 inhibitors
09/25/2014WO2014146604A1 Fused ring compound having gpr40 receptor function regulating action
09/25/2014WO2014146553A1 Flavonoid derivatives and use thereof
09/25/2014WO2014146494A1 Β-aminocarbonyl compound, preparation method, pharmaceutical composition and use thereof
09/25/2014WO2014146493A1 Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
09/25/2014WO2014146492A1 N-(2-cyano heterocyclyl)pyrazolo pyridones as janus kinase inhibitors
09/25/2014WO2014146491A1 Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors
09/25/2014WO2014146490A1 Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors
09/25/2014WO2014146486A1 Three-level cyclic amine alk kinase inhibitor for treating cancer
09/25/2014WO2014146249A1 Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors
09/25/2014WO2014146246A1 Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors
09/25/2014WO2014146218A1 Usage of mycophenolate mofetil or salt thereof in preparing drug for resisting against influenza virus
09/25/2014WO2013082345A9 Aryl dihydropyridinones and piperidinones as mgat2 inhibitors
09/25/2014US20140288623 Apparatus for treating cerebral neurovascular disorders including headaches by neural stimulation
09/25/2014US20140288483 Administration of antibiotics and therapeutic agents
09/25/2014US20140288481 Transdermal patch with non-water soluble adhesive and anesthetic
09/25/2014US20140288347 Compounds useful as inhibitors of atr kinase
09/25/2014US20140288295 Oligomer conjugates of heteropentacyclic nucleosides
09/25/2014US20140288290 Antisense design
09/25/2014US20140288187 Cocoa-based food products
09/25/2014US20140288186 Method for lowering blood glucose and method for treating hepatic disease, obesity and diabetes
09/25/2014US20140288182 Use of carbamide peroxide injection in preparation of virus inactivation medicaments for treating diseases
09/25/2014US20140288179 Stable solutions of treprostinil
09/25/2014US20140288178 INHIBITION OF c-MYC UBIQUITINATION TO PREVENT CANCER INITIATION AND PROGRESSION
09/25/2014US20140288177 Increasing Glutathione Levels for Therapy
09/25/2014US20140288175 Glycogen or polysaccharide storage disease treatment method
09/25/2014US20140288173 Anemia of cancer improving/prophylactic agent
09/25/2014US20140288172 Erythropoietin production-promoting agent
09/25/2014US20140288168 Novel use of eupatilin
09/25/2014US20140288166 Use of histone deacetylase inhibitors in changing mrjp3 protein in royal jelly
09/25/2014US20140288163 Thymidine kinase gene
09/25/2014US20140288162 Methods, compositions and screens for therapeutics for the treatment of synovial sarcoma
09/25/2014US20140288160 Cleavable lipids
09/25/2014US20140288154 Lipid Formulated Compositions and Methods for Inhibiting Expression of Eg5 And VEGF Genes
09/25/2014US20140288147 Methods of manipulating the fate of cells
09/25/2014US20140288146 Novel trialkyl cationic lipids and methods of use thereof
09/25/2014US20140288143 Bladder cancer treatment and methods
09/25/2014US20140288142 Nitric oxide donor compounds
09/25/2014US20140288139 Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
09/25/2014US20140288138 Angiotensin II Receptor Antagonist for the Prevention or Treatment of Systemic Diseases in Cats
09/25/2014US20140288137 Compositions and methods of treatment of inflammatory skin conditions using allantoin
09/25/2014US20140288136 Methods and uses of cytochrome p450 inhibitors
09/25/2014US20140288126 Organic compounds
09/25/2014US20140288125 N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
09/25/2014US20140288122 Method for inhibiting platelet aggregation
09/25/2014US20140288121 Asthma
09/25/2014US20140288117 Use of cysteamine in treating parkinson's disease
09/25/2014US20140288115 Compositions and methods for treating brain cancer
09/25/2014US20140288114 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
09/25/2014US20140288113 Extended Release Compositions Comprising Hydrocodone And Acetaminophen For Rapid Onset And Prolonged Analgesia That May Be Administered Without Regard To Food
09/25/2014US20140288112 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
09/25/2014US20140288108 Process for the preparation of solid dispersion of lopinavir and ritonavir
09/25/2014US20140288103 Neosaxitoxin Combination Formulations for Prolonged Local Anesthesia
09/25/2014US20140288102 Prevention of recurrences of urethral strictures following conventional therapy
09/25/2014US20140288098 Bruton's Tyrosine Kinase As Anti-Cancer Drug Target
09/25/2014US20140288095 Pyridopyrimidinone inhibitors of viruses
09/25/2014US20140288094 Pyrazolopyridyl compounds as aldosterone synthase inhibitors
09/25/2014US20140288091 Mono-fluoro beta-secretase inhibitors
09/25/2014US20140288088 Inhibitors of the Renal Outer Medullary Potassium Channel
09/25/2014US20140288087 Niche targeting of quiescent cancer stem cells
09/25/2014US20140288086 Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
09/25/2014US20140288085 Methods for the Treatment of Cardiovascular Conditions
09/25/2014US20140288079 Sgc stimulators of sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
09/25/2014US20140288078 Use of phosphodiesterase inhibitors for treating multidrug resistance
09/25/2014US20140288075 Isoxazole compound for the treatment of cancer
09/25/2014US20140288073 Method of Treating Gastrointestinal Stromal Tumors
09/25/2014US20140288070 Compounds and methods for kinase modulation, and indications therefor
09/25/2014US20140288069 Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
09/25/2014US20140288066 Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mtor inhibitors
09/25/2014US20140288062 Heteroaryl compounds and methods of use thereof
09/25/2014US20140288060 Selective inhibition of MALT1 protease by phenothiazine derivatives
09/25/2014US20140288059 Therapeutic compositions and methods
09/25/2014US20140288058 Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
09/25/2014US20140288057 Method and composition for treating alzheimer-type dementia
09/25/2014US20140288056 Methods for non-toxic treatment for drug withdrawal
09/25/2014US20140288054 Genetic markers of mental illness
09/25/2014US20140288053 Anticancer pyridopyrazines via the inhibition of fgfr kinases
09/25/2014US20140288051 Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
09/25/2014US20140288050 Modulators of opioid receptors and methods of use thereof
09/25/2014US20140288049 2-Thiopyrimidinones
09/25/2014US20140288047 Benzoxazepin pi3k inhibitor compounds and methods of use
09/25/2014US20140288040 Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection
09/25/2014US20140288039 Lipobalanced long chain testosterone prodrugs for oral delivery
09/25/2014US20140288038 Device for transdermal administration of drugs including acrylic polymers
09/25/2014US20140288035 18-methyl-6,7-methylene-3-oxo-17-pregn-4-ene-21,17b-carbolactones, pharmaceutical preparations comprising said compounds and use thereof in the treatment of endometriosis
09/25/2014US20140288034 Compound capable of binding s1p receptor and pharmaceutical use thereof
09/25/2014US20140288033 Crystalline forms of a biphenyl compound
09/25/2014US20140288032 Agents and devices for use in prevention of restenosis
09/25/2014US20140288031 Methods of treating heavy menstrual bleeding
09/25/2014US20140288030 Compositions for improving cell viability and methods of use thereof
09/25/2014US20140288029 Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine
09/25/2014US20140288028 Novel pharmaceutical salts and polymorphs of a factor xa inhibitor
09/25/2014US20140288027 Derivative of Butylphthalide and Preparation Method and Use Thereof
09/25/2014US20140288024 Cyclodextrin-based polymers for therapeutics delivery
09/25/2014US20140288023 Cyclodextrin-based polymers for therapeutics delivery
09/25/2014US20140288021 Composition Comprising Arabinogalactan and Polyphenols From Larch Trees
09/25/2014US20140288018 Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8
1 ... 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 ... 7860